Allosteric modulation of GluN2C/GluN2D-containing NMDA receptors bidirectionally modulates dopamine release: Implication for Parkinson's disease

British Journal of Pharmacology

Volumn 171, Issue 16, 2014, Pages 3938-3945

  Zhang, X ^a   Feng, Z J ^a   Chergui, K ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)[6,7 DIMETHOXY 1 [(4 METHOXYPHENOXY)METHYL] 3,4 DIHYDROISOQUINOLIN 2(1H) YL]METHANONE; AMINO ACID RECEPTOR AFFECTING AGENT; ANTIPARKINSON AGENT; DOPAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2C; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D; OXIDOPAMINE; PIRENZEPINE; UNCLASSIFIED DRUG; (3-CHLOROPHENYL)(6,7-DIMETHOXY-1-((4-METHOXYPHENOXY)METHYL)-3,4-DIHYDROISOQUINOLIN-2(1H)-YL)METHANONE; ISOQUINOLINE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR2C NMDA RECEPTOR; NR2D NMDA RECEPTOR;

ALLOSTERISM; AMPEROMETRY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASYMPTOMATIC DISEASE; BRAIN SLICE; CHOLINERGIC ACTIVITY; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; EVOKED RESPONSE; INTERNEURON; LONG TERM POTENTIATION; MALE; MOUSE; NERVE CELL DEGENERATION; NERVE POTENTIAL; NERVE STIMULATION; NEUROMODULATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SUBSTANTIA NIGRA; ANIMAL; BRAIN; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALLOSTERIC REGULATION; ANIMALS; BRAIN; DOPAMINE; INTERNEURONS; ISOQUINOLINES; MALE; MICE; MICE, INBRED C57BL; OXIDOPAMINE; PARKINSONIAN DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84905041359     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12758     Document Type: Article

References (48)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ligand-gated ion channels. Br J Pharmacol 170: 1582-1603.
3. Bagetta V, Ghiglieri V, Sgobio C, Calabresi P, Picconi B, (2010). Synaptic dysfunction in Parkinson's disease. Biochem Soc Trans 38: 493-497.
4. Bergman H, Deuschl G, (2002). Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Mov Disord 17 (Suppl. 3): S28-S40.
5. Blandini F, Nappi G, Tassorelli C, Martignoni E, (2000). Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62: 63-88.
6. Bloomfield C, O'Donnell P, French SJ, Totterdell S, (2007). Cholinergic neurons of the adult rat striatum are immunoreactive for glutamatergic N-methyl-d-aspartate 2D but not N-methyl-D-aspartate 2C receptor subunits. Neuroscience 150: 639-646.
7. Brothwell SLC, Barber JL, Monaghan DT, Jane DE, Gibb AJ, Jones S, (2008). NR2B- and NR2D-containing synaptic NMDA receptors in developing rat substantia nigra pars compacta dopaminergic neurones. J Physiol 586: 739-750.
8. Caulfield MP, Birdsall NJM, (1998). International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50: 279-290.
9. Chergui K, (2011). Dopamine induces a GluN2A-dependent form of long-term depression of NMDA synaptic responses in the nucleus accumbens. Neuropharmacology 60: 975-981.
10. Chergui K, Suaud-Chagny MF, Gonon F, (1994). Nonlinear relationship between impulse flow, dopamine release and dopamine elimination in the rat brain in vivo. Neuroscience 62: 641-645.
11. Costa BM, Feng B, Tsintsadze TS, Morley RM, Irvine MW, Tsintsadze V, et-al. (2009). N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse. J Pharmacol Exp Ther 331: 618-626.
12. Dehorter N, Michel FJ, Marissal T, Rotrou Y, Matrot B, Lopez C, et-al. (2011). Onset of pup locomotion coincides with loss of NR2C/D-mediated cortico-striatal EPSCs and dampening of striatal network immature activity. Front Cell Neurosci 5: 24.
13. Doods HN, Entzeroth M, Ziegler H, Mayer N, Holzer P, (1994). Pharmacological profile of selective muscarinic receptor antagonists on guinea-pig ileal smooth muscle. Eur J Pharmacol 253: 275-281.
14. Dunah AW, Yasuda RP, Wang Y-H, Luo J, Dávila-García MI, Gbadegesin M, et-al. (1996). Regional and ontogenic expression of the NMDA receptor subunit NR2D protein in rat brain using a subunit-specific antibody. J Neurochem 67: 2335-2345.
15. Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT, (2004). Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br J Pharmacol 141: 508-516.
16. Feng Z-J, Zhang X, Chergui K, (2014). Allosteric modulation of NMDA receptors alters neurotransmission in the striatum of a mouse model of Parkinson's disease. Exp Neurol 255: 154-160.
17. Gerfen CR, (1992). The neostriatal mosaic: multiple levels of compartmental organization. J Neural Transm Suppl 36: 43-59.
18. Gogas KR, (2006). Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 6: 68.
19. Hallett PJ, Standaert DG, (2004). Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 102: 155-174.
20. Harney SC, Anwyl R, (2012). Plasticity of NMDA receptor-mediated excitatory postsynaptic currents at perforant path inputs to dendrite-targeting interneurons. J Physiol 590: 3771-3786.
21. Harney SC, Jane DE, Anwyl R, (2008). Extrasynaptic NR2D-containing NMDARs are recruited to the synapse during LTP of NMDAR-EPSCs. J Neurosci 28: 11685-11694.
22. Jones S, Gibb AJ, (2005). Functional NR2B- and NR2D-containing NMDA receptor channels in rat substantia nigra dopaminergic neurones. J Physiol 569: 209-221.
23. Kalia LV, Brotchie JM, Fox SH, (2013). Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Mov Disord 28: 131-144.
24. Kawaguchi Y, (1993). Physiological, morphological, and histochemical characterization of 3 classes of interneurons in rat neostriatum. J Neurosci 13: 4908-4923.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
26. Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB Jr, Young AB, (1995). NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 15 (7 Pt 2): 5297-5307.
27. Loftis JM, Janowsky A, (2003). The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther 97: 55-85.
28. Logan SM, Partridge JG, Matta JA, Buonanno A, Vicini S, (2007). Long-lasting NMDA receptor-mediated EPSCs in mouse striatal medium spiny neurons. J Neurophysiol 98: 2693-2704.
29. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
30. Mullasseril P, Hansen KB, Vance KM, Ogden KK, Yuan H, Kurtkaya NL, et-al. (2010). A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. Nat Commun 1: 90.
31. Ogden KK, Traynelis SF, (2011). New advances in NMDA receptor pharmacology. Trends Pharmacol Sci 32: 726-733.
32. Ogden KK, Khatri A, Traynelis SF, Heldt SA, (2014). Potentiation of GluN2C/D NMDA receptor subtypes in the amygdala facilitates the retention of fear and extinction learning in mice. Neuropsychopharmacology 39: 625-637.
33. Paoletti P, Bellone C, Zhou Q, (2013). NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14: 383-400.
34. Paxinos G, Franklin KBJ, (2001). The Mouse Brain in Stereotaxic Coordinates. Academic: San Diego, CA.
35. Perez XA, Bordia T, McIntosh JM, Quik M, (2010). α6β2* and α4β2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease. Mol Pharmacol 78: 971-980.
36. Pisani A, Bernardi G, Ding J, Surmeier DJ, (2007). Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 30: 545-553.
37. Rice ME, Cragg SJ, (2004). Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci 7: 583-584.
38. Schotanus S, Chergui K, (2008). NR2A-containing NMDA receptors depress glutamatergic synaptic transmission and evoked-dopamine release in the mouse striatum. J Neurochem 106: 1758-1765.
39. Standaert DG, Landwehrmeyer GB, Kerner JA, Penney JB Jr, Young AB, (1996). Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Brain Res Mol Brain Res 42: 89-102.
40. Suárez F, Zhao Q, Monaghan DT, Jane DE, Jones S, Gibb AJ, (2010). Functional heterogeneity of NMDA receptors in rat substantia nigra pars compacta and reticulata neurones. Eur J Neurosci 32: 359-367.
41. Tong H, Gibb AJ, (2008). Dopamine D1 receptor inhibition of NMDA receptor currents mediated by tyrosine kinase-dependent receptor trafficking in neonatal rat striatum. J Physiol 586: 4693-4707.
42. Tozzi A, de Iure A, Di Filippo M, Tantucci M, Costa C, Borsini F, et-al. (2011). The distinct role of medium spiny neurons and cholinergic interneurons in the D2/A2A receptor interaction in the striatum: implications for Parkinson's disease. J Neurosci 31: 1850-1862.
43. Wang Z, Kai L, Day M, Ronesi J, Yin HH, Ding J, et-al. (2006). Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. [See comment]. Neuron 50: 443-452.
44. Wenzel A, Villa M, Mohler H, Benke D, (1996). Developmental and regional expression of NMDA receptor subtypes containing the NR2D subunit in rat brain. J Neurochem 66: 1240-1248.
45. Zhang H, Sulzer D, (2004). Frequency-dependent modulation of dopamine release by nicotine. Nat Neurosci 7: 581-582.
46. Zhang H, Sulzer D, (2012). Regulation of striatal dopamine release by presynaptic auto-and heteroreceptors. Basal Ganglia 2: 5-13.
47. Zhang X, Andren PE, Greengard P, Svenningsson P, (2008). Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in l-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci U S A 105: 2163-2168.
48. Zhang X, Feng Z-J, Chergui K, (2014). GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease. J Neurochem 129: 581-590.